TEVA vs. MRK
Compare and contrast key facts about Teva Pharmaceutical Industries Limited (TEVA) and Merck & Co., Inc. (MRK).
Performance
TEVA vs. MRK - Performance Comparison
Loading graphics...
TEVA vs. MRK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
TEVA Teva Pharmaceutical Industries Limited | -3.08% | 41.61% | 111.11% | 14.47% | 13.86% | -16.99% | -1.53% | -36.45% | -18.63% | -46.18% |
MRK Merck & Co., Inc. | 15.65% | 9.79% | -6.26% | 1.01% | 49.42% | 1.75% | -7.20% | 22.27% | 39.95% | -1.49% |
Fundamentals
TEVA:
$35.48B
MRK:
$300.65B
TEVA:
$1.21
MRK:
$7.30
TEVA:
25.03
MRK:
16.55
TEVA:
0.19
MRK:
0.01
TEVA:
2.04
MRK:
4.65
TEVA:
4.48
MRK:
5.79
TEVA:
$17.26B
MRK:
$65.01B
TEVA:
$8.94B
MRK:
$52.98B
TEVA:
$3.80B
MRK:
$28.80B
Returns By Period
In the year-to-date period, TEVA achieves a -3.08% return, which is significantly lower than MRK's 15.65% return. Over the past 10 years, TEVA has underperformed MRK with an annualized return of -5.21%, while MRK has yielded a comparatively higher 12.36% annualized return.
TEVA
- 1D
- 0.43%
- 1M
- -10.42%
- YTD
- -3.08%
- 6M
- 50.80%
- 1Y
- 97.84%
- 3Y*
- 50.64%
- 5Y*
- 21.38%
- 10Y*
- -5.21%
MRK
- 1D
- 0.46%
- 1M
- 0.27%
- YTD
- 15.65%
- 6M
- 36.22%
- 1Y
- 43.74%
- 3Y*
- 7.58%
- 5Y*
- 13.97%
- 10Y*
- 12.36%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TEVA vs. MRK — Risk / Return Rank
TEVA
MRK
TEVA vs. MRK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Teva Pharmaceutical Industries Limited (TEVA) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| TEVA | MRK | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.33 | 1.52 | +0.81 |
Sortino ratioReturn per unit of downside risk | 3.11 | 2.17 | +0.94 |
Omega ratioGain probability vs. loss probability | 1.42 | 1.28 | +0.14 |
Calmar ratioReturn relative to maximum drawdown | 4.44 | 2.52 | +1.92 |
Martin ratioReturn relative to average drawdown | 12.93 | 6.65 | +6.28 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| TEVA | MRK | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.33 | 1.52 | +0.81 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.50 | 0.60 | -0.10 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.11 | 0.55 | -0.66 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.31 | 0.49 | -0.18 |
Correlation
The correlation between TEVA and MRK is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
TEVA vs. MRK - Dividend Comparison
TEVA has not paid dividends to shareholders, while MRK's dividend yield for the trailing twelve months is around 2.75%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
TEVA Teva Pharmaceutical Industries Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.88% | 3.19% | 1.77% |
MRK Merck & Co., Inc. | 2.75% | 3.12% | 3.14% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.43% |
Drawdowns
TEVA vs. MRK - Drawdown Comparison
The maximum TEVA drawdown since its inception was -90.89%, which is greater than MRK's maximum drawdown of -68.61%. Use the drawdown chart below to compare losses from any high point for TEVA and MRK.
Loading graphics...
Drawdown Indicators
| TEVA | MRK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.89% | -68.61% | -22.28% |
Max Drawdown (1Y)Largest decline over 1 year | -21.79% | -15.16% | -6.63% |
Max Drawdown (5Y)Largest decline over 5 years | -43.70% | -43.44% | -0.26% |
Max Drawdown (10Y)Largest decline over 10 years | -88.71% | -43.44% | -45.27% |
Current DrawdownCurrent decline from peak | -55.29% | -3.60% | -51.69% |
Average DrawdownAverage peak-to-trough decline | -31.90% | -18.88% | -13.02% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.49% | 5.94% | +1.55% |
Volatility
TEVA vs. MRK - Volatility Comparison
Teva Pharmaceutical Industries Limited (TEVA) has a higher volatility of 11.82% compared to Merck & Co., Inc. (MRK) at 5.70%. This indicates that TEVA's price experiences larger fluctuations and is considered to be riskier than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| TEVA | MRK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.82% | 5.70% | +6.12% |
Volatility (6M)Calculated over the trailing 6-month period | 27.30% | 18.76% | +8.54% |
Volatility (1Y)Calculated over the trailing 1-year period | 42.20% | 29.07% | +13.13% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 42.76% | 23.30% | +19.46% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 47.20% | 22.68% | +24.52% |
Financials
TEVA vs. MRK - Financials Comparison
This section allows you to compare key financial metrics between Teva Pharmaceutical Industries Limited and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TEVA vs. MRK - Profitability Comparison
TEVA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Teva Pharmaceutical Industries Limited reported a gross profit of 2.66B and revenue of 4.71B. Therefore, the gross margin over that period was 56.4%.
MRK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Merck & Co., Inc. reported a gross profit of 15.20B and revenue of 16.40B. Therefore, the gross margin over that period was 92.7%.
TEVA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Teva Pharmaceutical Industries Limited reported an operating income of 1.27B and revenue of 4.71B, resulting in an operating margin of 26.9%.
MRK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Merck & Co., Inc. reported an operating income of 8.74B and revenue of 16.40B, resulting in an operating margin of 53.3%.
TEVA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Teva Pharmaceutical Industries Limited reported a net income of 480.00M and revenue of 4.71B, resulting in a net margin of 10.2%.
MRK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Merck & Co., Inc. reported a net income of 2.96B and revenue of 16.40B, resulting in a net margin of 18.1%.